reports
Collegium Reports First Quarter 2024 Financial Results
Collegium Reports First Quarter 2024 Financial Results – Generated Q1’24 Net Revenue of $144.9 Million – – Delivered Q1’24 Record Belbuca® Revenue of $50.7 Million; Total Prescriptions Up 4.2% Year-over-Year – – Achieved Q1’24 GAAP Net Income of $27.7 Million vs. Q1’23 GAAP Net Loss of $(17.4) Million – – Delivered Q1’24 Adjusted EBITDA of $92.4 Million, Up 5% Year-over-Year – – Board of Directors Authorized $35.0 Million Accelerated Share Repurchase Program – – Reaffirmed Full-Year 2024 Guidance – – Conference Call Scheduled for Today ...
Allakos Provides Business Update and Reports First Quarter 2024 Financ...
Allakos Provides Business Update and Reports First Quarter 2024 Financial Results SAN CARLOS, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the first quarter ended March 31, 2024. Recent Allakos Events Completed dosing in the single ascending dose (SAD) cohorts and multiple ascending dose (MAD) cohorts of the randomized, double-blind, placebo-controlled Phase 1 tri...
PDF Solutions® Reports First Quarter 2024 Results
PDF Solutions® Reports First Quarter 2024 Results SANTA CLARA, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- PDF Solutions, Inc. (Nasdaq: PDFS), a leading provider of comprehensive data solutions for the semiconductor ecosystem, today announced financial results for its first quarter ended March 31, 2024. Financial Highlights of First Quarter 2024 and Other Updates Analytics revenues of $38.5 million, up 6% over last year’s comparable quarterQuarterly revenues of $41.3 million, up 1% over last year’s comparable quarterGAAP gross margin of 67% and Non-GAAP gross margin of 72%GAAP diluted...
Navitas Semiconductor Announces First Quarter 2024 Financial Results
Navitas Semiconductor Announces First Quarter 2024 Financial Results Q1 revenue up 73% year-on-year, driven by continued GaN adoption in mobile fast chargers and AI-based data centers, and SiC sales in EV, solar and industrial applications.New GaNSlim™ technology expected to advance GaN-based systems’ integration, ease-of-use, time-to-market, and manufacturability, which enable lower system costs compared to silicon-based solutions. TORRANCE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: NVTS), the industry leader in next-generation power semiconductors, today announced unaudited ...
BLINK CHARGING ANNOUNCES FIRST QUARTER REVENUE GROWTH OF 73% TO $37.6 ...
BLINK CHARGING ANNOUNCES FIRST QUARTER REVENUE GROWTH OF 73% TO $37.6 MILLION AND GROSS MARGIN OF 36% ●First quarter 2024 total revenues increased 73% to $37.6 million compared to $21.7 million in first quarter of 2023 ●68% increase in product revenues to $27.5 million in first quarter of 2024 compared to $16.4 million in first quarter of 2023 ●72% increase in service revenues to $8.2 million in first quarter of 2024 compared to $4.8 million in first quarter 2023 ●195% increase in gross profit to $13.4 million in first quarter of 2024 compared to $4.5 million in first quarter of 2023 ●36% ...
Achieve Life Sciences Reports Financial Results for First Quarter 2024...
Achieve Life Sciences Reports Financial Results for First Quarter 2024 and Provides Corporate Update Company to host conference call at 4:30 PM EDT today, Thursday, May 9, 2024 SEATTLE and VANCOUVER, British Columbia, May 09, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage pharmaceutical company dedicated to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced its financial results for the first quarter of 2024 and provided an update on the cytisinicline development program. Rece...
MacroGenics Provides Update on Corporate Progress, First Quarter 2024 ...
MacroGenics Provides Update on Corporate Progress, First Quarter 2024 Financial Results and Interim TAMARACK Phase 2 Study Data Presentation of interim TAMARACK Phase 2 study data: updated safety and preliminary efficacy of vobra duo in mCRPC patientsConference call scheduled for today at 4:30 p.m. ET ROCKVILLE, Md., May 09, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent cor...
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
Rhythm Pharmaceuticals Announces New Employment Inducement Grants BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that on May 6, 2024, the Compensation Committee of Rhythm’s board of directors granted inducement restricted stock units, or RSUs, covering an aggregate of 15,150 shares of its common stock to seven new employees. These inducement RSUs are subject to the terms of the ...
Research Frontiers Reports First Quarter 2024 Financial Results and Wi...
Research Frontiers Reports First Quarter 2024 Financial Results and Will Host a Conference Call at 5:30p.m. Today WOODBURY, N.Y., May 09, 2024 (GLOBE NEWSWIRE) -- Research Frontiers Inc. (Nasdaq: ) announced its financial results for its first quarter of 2024. Management will host a conference call today at 5:30 p.m. Eastern Time to discuss its financial and operating results as well as recent developments. •Who: Joseph M. Harary, President & CEO •Date/Time: Thursday, May 9, 2024, 5:30 PM ET (please note new start time) •Dial-in Information:1-888-334-5785 •Replay: Available on Friday,...
Eton Pharmaceuticals Reports First Quarter 2024 Financial Results
Eton Pharmaceuticals Reports First Quarter 2024 Financial Results • Q1 2024 revenue of $8.0 million, representing 50% growth over Q1 2023 and the 13th straight quarter of sequential product sales growth• Acquired PKU GOLIKE®, launched Nitisinone, and submitted a new drug application (NDA) for product candidate ET-400• Management to hold conference call today at 4:30pm ET DEER PARK, Ill., May 09, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare ...
Xenon Pharmaceuticals Reports First Quarter 2024 Financial Results and...
Xenon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update Phase 3 epilepsy program continues to progress with anticipated completion of patient enrollment in X-TOLE2 in late 2024 to early 2025 Successful “end-of-Phase 2” interactions with FDA in MDD; Phase 3 program on track to initiate in the second half of the year Azetukalner now the international nonproprietary name (INN) and United States adopted name (USAN) for XEN1101 Conference call at 4:30 pm ET today VANCOUVER, British Columbia, May 09, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals In...
First Quantum Minerals Announces Voting Results for the Election of Di...
First Quantum Minerals Announces Voting Results for the Election of Directors TORONTO, May 09, 2024 (GLOBE NEWSWIRE) -- First Quantum Minerals Ltd. (“First Quantum” or “the Company”) (TSX: FM) announced that the nominees listed in the Management Information Circular for the 2024 Annual Meeting of Shareholders were elected as directors of First Quantum. In total, 698,930,219 shares were voted at the meeting, representing 83.85% of the issued and outstanding shares of the Company. Detailed results of the vote for the election of directors held at the Annual Meeting on May 9, 2024 are set ou...
Acutus Medical Reports First Quarter 2024 Financial Results
Acutus Medical Reports First Quarter 2024 Financial Results CARLSBAD, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (OTC: AFIB) today reported results for the first quarter of 2024. Recent Highlights: First quarter revenue from Continuing Operations of $3.6 million grew 192% year-over-year, from $1.2 million in the same quarter last year..Operating expenses for continuing operations were $3.3 million, a reduction of 38% compared to the same period last year.Recorded $2.8 million in gain on sale of business, an increase of 131% compared to ...
Fate Therapeutics Reports First Quarter 2024 Financial Results and Bus...
Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates First Lupus Patient Treated with FT819 CAR T-cell Product Candidate in Phase 1 Autoimmunity Study; Future Clinical Development of FT819 to Focus Exclusively on Autoimmune Disease Enrollment Initiated with FT522 CAR NK Cell Product Candidate in Conditioning-free Treatment Arm of Phase 1 B Cell Lymphoma Study First Patient Treated with FT825 / ONO-8250 CAR T-cell Product Candidate in Phase 1 Solid Tumor Study $391 Million in Cash, Cash Equivalents, and Investments SAN DIEGO, May 09, 2024 ...
Recursion Provides Business Updates and Reports First Quarter 2024 Fin...
Recursion Provides Business Updates and Reports First Quarter 2024 Financial Results On track to read out multiple Phase 2 clinical trials in the coming quarters, beginning in Q3 2024Performance benchmarking completed on BioHive-2, Recursion's next generation supercomputer, which will support the construction of foundation models across biology, chemistry, and patient outcomesTranscriptomics technology has continued to be scaled to more than 1 million transcriptomes with a whole-genome knockout transcriptomics map to be completed in the coming quartersEntered into a multi-year agreement wit...
Coherus BioSciences Reports First Quarter 2024 Financial Results and P...
Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update – Net revenue of $77.1 million in Q1 2024 – – CRI and ENB Therapeutics development partnership for toripalimab in ovarian cancer – – New debt and royalty financing replaces $75 million term loan, with debt maturity of May 2029 – – Conference call today at 5:00 p.m. Eastern Time – REDWOOD CITY, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today reported financial results for the quarter ended March 31, 2024 and recent business hi...
American Shared Hospital Services Announces Closing of Acquisition of ...
American Shared Hospital Services Announces Closing of Acquisition of 60% Majority Interest in Three Radiation Therapy Cancer Centers in Rhode Island - Adds $9-$10 million in Annual Revenue with Positive Net Income Contribution - - Acquisition more than Doubles Backlog to over $210 million - - Expands U.S. Footprint and Product Offering - SAN FRANCISCO, May 09, 2024 (GLOBE NEWSWIRE) -- American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy cancer treatment s...
Invivyd Reports First Quarter 2024 Financial Results and Recent Busine...
Invivyd Reports First Quarter 2024 Financial Results and Recent Business Highlights Launched PEMGARDA™ in the U.S. for COVID-19 pre-exposure prophylaxis (PrEP) in certain adults and adolescents with moderate-to-severe immune compromiseReported interim exploratory COVID-19 clinical event data from CANOPY Phase 3 clinical trial of VYD222 Received product-specific reimbursement codes covering PEMGARDA from the U.S. Centers for Medicare & Medicaid Services (CMS), covering approximately half of target populationAnnounced plans to pursue rapid immunobridging pathway to potential EUA for COVID-19 ...
eFFECTOR Therapeutics Reports First Quarter 2024 Financial Results and...
eFFECTOR Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update Dose escalation of zotatifin in the ZFA triplet ongoing at 0.14 mg/kg, with RP2D expected in H2 2024 Raised $15.0 million in gross proceeds from registered direct financing, extending cash runway into first quarter of 2025 SOLANA BEACH, Calif. and REDWOOD CITY, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today reported financial results for t...
Urbana Corporation Has Filed 2024 First Quarter Interim Financial Stat...
Urbana Corporation Has Filed 2024 First Quarter Interim Financial Statements /NOT FOR DISTRIBUTION TO U.S. WIRE SERVICES OR FOR DISSEMINATION IN THE U.S./ TORONTO, May 09, 2024 (GLOBE NEWSWIRE) -- Urbana Corporation (TSX & CSE: URB & URB.A) Urbana Corporation announces today that it has filed its unaudited interim Financial Statements and Management’s Discussion and Analysis for the three-month period ended March 31, 2024 with the applicable Canadian securities regulators. PDF versions of the documents are available at and at . For further information contact: Elizabeth Naumovski In...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.